Gelesis Holdings, Inc. (GLSHQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Oct 31, 2025
Gelesis Holdings Revenue
Gelesis Holdings had revenue of $1.11M in the quarter ending June 30, 2023, a decrease of -87.66%. This brings the company's revenue in the last twelve months to $12.14M, down -45.79% year-over-year. In the year 2022, Gelesis Holdings had annual revenue of $25.77M with 130.37% growth.
Revenue (ttm)
12.14M
Revenue Growth
-45.79%
P/S Ratio
0.00
Revenue / Employee
130.54K
Employees
93
Market Cap
7.33K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 25.77M | 14.58M | 130.37% |
| Dec 31, 2021 | 11.19M | -10.26M | -47.84% |
| Dec 31, 2020 | 21.44M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2014 | 209.00K | -5.30M | -96.20% |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hard to Treat Diseases | 6.16M |
| Statera Biopharma | 3.69M |
| Theralink Technologies | 635.45K |
| Syros Pharmaceuticals | 386.00K |
| Therapeutic Solutions International | 85.32K |
| Navidea Biopharmaceuticals | 610.00 |